REGISTER
InnoCare at Ten: 5-Year Drug Launch, First Profit, and China’s NRDL Talks
InnoCare, founded in 2015, brought BTK inhibitor orelabrutinib to market in five years and reported its first annual profit in 2025. China’s National Reimbursement Drug List (NRDL) negotiations now let about 80% of new drugs reach the NRDL within two years. In 2025, the company closed four global deals, including a $2-billion-plus out-licensing deal for orelabrutinib in multiple sclerosis. Prof. Huang Huiqiang of Sun Yat-sen University Cancer Center adds perspective.

The “annual adjustment” of the National Reimbursement Drug List (NRDL) has significantly compressed the wait between approval and reimbursement, with about 80% of innovative drugs now reaching the list within two years of launch. For the broader industry, the real test lies beyond the list—from “NRDL inclusion,” to “hospital availability,” to actual physician prescribing—and ultimately, to one fundamental goal: ensuring value-based care reaches every patient.

Hospitals are the critical bridge for this “last mile.” MedJ, a platform that connects more than 3 million healthcare professionals, serves both as a witness to policy rollout and as an important bridge between medical insurance, industry, and clinical practice.

MedJ recently joined the National Healthcare Security Administration (NHSA) Chinese Medical Insurance Support for High-Quality Pharmaceutical Industry Development research initiative, visiting four innovative drugmakers: Innovent Biologics, Hengrui Pharmaceuticals, InnoCare, and Akeso.

This article is the third installment of the “Path to Value-Based Care” series, profiling InnoCare.

Bringing a new drug to market takes an industry-average ten years and ten billion dollars. InnoCare brought its first innovative drug, the BTK inhibitor orelabrutinib, to market in just over five years and turned its first annual profit in its tenth year—a pace that is uncommon in the biopharmaceutical industry.

At the NHSA-organized “2026 Media Research Tour,” InnoCare credited this “acceleration” to the support of national medical insurance policy.

Five Years for One Drug, Ten Years for Profit

In 2015, Shi Yigong, then a professor at Tsinghua University, approached translational medicine expert Cui Jixun to co-found a biopharmaceutical company focused on new drug development. At a time when China’s innovative drug industry was just taking shape, the founders chose a relatively niche but clinically urgent path, focusing on malignant tumors and autoimmune diseases—both areas with substantial unmet medical needs.

The BTK inhibitor orelabrutinib, a targeted drug that acts on B-cell signaling to inhibit malignant B-cell proliferation and survival, is InnoCare’s first commercial product. The industry consensus holds that a new drug takes an average of ten years and ten billion RMB to reach patients. Orelabrutinib took just over five years from the company’s founding to its December 2020 marketing approval.

The acceleration, in the view of Chen Shaofeng, InnoCare’s Chief Business Officer, reflects “a startup’s high efficiency” combined with strong policy support.

“Orelabrutinib’s initial project target was actually autoimmune disease, such as systemic lupus erythematosus and multiple sclerosis, rather than lymphoma. Regulators proactively recommended adding lymphoma when they saw early data, and the company pivoted quickly,”Chen Shaofeng said. “Approval also benefited from the conditional approval pathway that allows submission based on single-arm Phase II data, accelerating commercialization.”

December 2020 saw orelabrutinib first approved for R/R mantle cell lymphoma (MCL) and CLL/SLL (hematologic malignancies). The drug did not file for its first autoimmune indication (primary immune thrombocytopenia, ITP) until 2026, and systemic lupus erythematosus (SLE) remains in Phase III trials.

In 2025, two more InnoCare drugs reached the market: tancitumamab (brand: Mingnuokai®), China’s first approved CD19 monoclonal antibody for R/R diffuse large B-cell lymphoma (DLBCL); and zoleritinib (brand: Yinuoxin®), China’s first homegrown next-generation TRK inhibitor. InnoCare now commercializes three innovative drugs.

In addition, more than 10 candidate products are in clinical-stage development, with over 30 clinical trials cumulatively and more than 600 patent applications. Among these, the next-generation BCL2 inhibitor mesutoclax (ICP-248) presented first-time data at the 2026 ASCO Annual Meeting as an oral presentation.

According to the company, mesutoclax combined with orelabrutinib in a “fixed-duration” regimen may enable CLL/SLL patients to achieve long-term remission off therapy. Chen Shaofeng suggested this lymphoma subtype could potentially reach clinical cure.

The speed extends beyond R&D. Gao Nan, InnoCare’s Chief Operating Officer, noted that construction at the Guangzhou base began at the end of 2018 on a hillside site. From groundbreaking to commercial production in 2022 took less than four years—a pace he characterized as among the fastest in the Greater Bay Area pharmaceutical industry. The site integrates active pharmaceutical ingredient (API) production, intermediates, and finished dosage forms on a single full industrial chain, offering efficiency and cost advantages.

Even more critically, R&D and manufacturing are co-located within the same campus. As Gao Nan described, drug quality and manufacturing considerations are incorporated early in R&D, so process optimization can be addressed quickly once the product is approved—a key reason InnoCare can bring new drugs to market rapidly.

2025 marked InnoCare’s tenth anniversary and its first full-year profit: total revenue of 2.37 billion RMB, up 135.3% year-on-year, with net profit attributable to shareholders of 640 million RMB. The momentum continued into 2026, with first-quarter net profit of approximately 104 million RMB, up 607.7% year-on-year—making InnoCare one of the fastest post-IPO biopharmaceutical companies to reach profitability.

Innovative drugmakers can reach profitability within ten years. Beyond the continued ramp of three marketed products, international expansion also played an important role.

In 2025, InnoCare Pharma concluded international collaborations for four assets, with a total transaction value reaching $2.5 billion. The most significant deal was the global exclusive licensing agreement signed in October of that year with U.S.-based Zenas BioPharma for orelabrutinib in the field of multiple sclerosis, valued at over $2 billion—setting a new record for outbound licensing of China-developed small-molecule autoimmune drugs at the time.

Looking toward its 10th-anniversary milestone, InnoCare set its next strategic target, “INNOCARE 10”: by 2030, secure approval for 5-6 innovative drugs, complete globalization of 3-4 products, lead in hematologic oncology, and become a strong competitor in autoimmune diseases and solid tumors.

Two Books, One Balance

InnoCare’s rapid growth, in Chen Shaofeng’s view, rests on “medical insurance empowerment.”

He shared the data: orelabrutinib posted full-year 2021 sales of 215 million RMB after its late-2020 approval. After its first two indications passed NRDL negotiations at the end of 2021, with execution beginning in 2022, sales jumped to 566 million RMB that year, up 163.63% year-on-year.

Subsequent additions of more indications—including marginal zone lymphoma (MZL)—and their NRDL inclusion drove continuous growth: 671 million RMB in 2023, exceeding 1 billion RMB in 2024, and 1.443 billion RMB in 2025 across all three marketed products, accounting for approximately 60% of total revenue.

Chen Shaofeng noted that growth has remained near 50% year-on-year, calling this “the most vivid case of medical insurance empowerment of China’s innovative drug industry, allowing patients to access drugs at more affordable prices while enabling companies to earn reasonable returns.”

All four approved indications of orelabrutinib are now included in the NRDL, with marginal zone lymphoma (MZL) the only BTK inhibitor covered in this indication. Orelabrutinib is also the only Level-1 recommendation in the 2025 edition of the Chinese Society of Clinical Oncology (CSCO) Lymphoma Diagnosis and Treatment Guidelines.

While corporate revenues grow, patient out-of-pocket costs shrink. Take 101-year-old “Grandma Zhang,” diagnosed with lymphoma at Shanghai Zhongshan Hospital. Her family initially worried that her age would make treatment too difficult, but oral orelabrutinib proved far more convenient than radiotherapy.

“The doctor said I should start with two pills a day because of my age. I had no discomfort, then we increased to three. Now I can walk without help,”she said. Asked what drug she was taking, she immediately answered, “Orelabrutinib, made in China!” Her family noted that she takes her medication very seriously and often remarks, “These national drugs are good; I have to be properly treated.” With NRDL inclusion, her family’s financial burden has eased significantly.

At the research event, a patient representative offered a more specific calculation: monthly treatment costs originally ran above 10,000 RMB, dropping to roughly 1,000 RMB after reimbursement.

Prof. Huang Huiqiang, Deputy Director of Medical Oncology and Head of the Lymphoma Research Center at Sun Yat-sen University Cancer Center, commented: “Recent national medical insurance policies have been very supportive. Many conditions that once required full out-of-pocket payment can now be reimbursed, including some conditionally approved products—our patients are genuinely benefiting.”

In the balance between growth and relief, medical insurance now links “patients being able to afford treatment” with “companies being able to survive.”

Beyond cost, the value of domestic innovative drugs also comes from clinical outcomes. Prof. Huang, a leading Chinese expert in hematologic oncology and lymphoma whose research has twice been incorporated into NCCN guidelines, and his team participated in pre-marketing clinical studies of orelabrutinib and continue to track its post-marketing real-world performance: “We regularly receive FDA and EU-level inspections. Chinese standards are fully aligned with international ones. For example, orelabrutinib shows a better safety profile and better efficacy than first-generation BTK inhibitors. This has been independently verified.”

Faster, and More Precise

“Real support” from medical insurance and “real innovation” from drugmakers are widely recognized as a two-way partnership. Beneath this consensus, practical questions remain to be worked out between companies and the NHSA.

First, the question of speed.

The NHSA previously disclosed that the time from approval to NRDL inclusion has dropped from approximately five years to about one year, with about 80% of innovative drugs reaching the NRDL within two years of approval. In 2023, 57 new listings were added; in 2024, 91 new listings were added, with 33 achieving same-year approval-and-listing.

In May 2026, the NHSA released the “2026 National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List Adjustment Work Plan and Commercial Health Insurance Innovative Drug List Adjustment Work Plan,” introducing a “pre-declaration mechanism” that allows drugs to apply before completing technical review or formal approval.

Industry observers widely view this as opening the “pre-launch NRDL negotiation” era, which may ease pressure on companies racing to secure approval just before negotiation windows.

Beyond speed, “how prices are set after NRDL inclusion” has long been a top concern. The 2026 negotiation plan introduced a “pre-communication mechanism” enabling companies to understand the NHSA’s evaluation logic earlier and prepare evidence on health economics, clinical value, and pricing.

Renewal rules also favor Class 1 innovative drugs with true source-of-innovation value. Beyond the existing rule allowing drugs listed for four consecutive years to enjoy “half the price cut,” companies may also actively apply for “renegotiation” when triggered under the tiered price reduction mechanism, with no guarantee that the final reduction will exceed that of standard simplified renewal.

These adjustments provide a more precise price metric for “the value of innovation.” However, individual drugs may still encounter novel situations. InnoCare’s flagship product orelabrutinib now faces a situation without precedent: originally approved as a hematologic oncology drug, the company has filed ITP and recorded positive Phase III results in SLE, meaning the drug is poised to span both oncology and autoimmune indications. The autoimmune patient population is typically far larger than that for hematologic malignancies.

“This product will be a special case—both an oncology drug and an autoimmune drug—without a clear precedent in the industry,”InnoCare representatives noted.

Finding a renewal agreement that balances patient population, clinical value, and original-indication pricing will be a new topic for the company and the NHSA to navigate together.

Prof. Huang offered perspective at a more fundamental level. He noted that China's current real-world data are not yet systematic or refined enough, and recommended selecting representative clinical centers to establish high-quality real-world data collection mechanisms: “so commercial insurance companies can price policies accurately without losses, and at the national level, these data can support future medical insurance and hospital policy decisions.”

Some questions have answers; others remain on the agenda of companies and the NHSA. As Chen Shaofeng put it, medical insurance is empowering China’s innovative drug industry to move from “following”and “running alongside” to “leading.”

0
0
Loading